Rheonix, manufacturer of a microfluidic molecular testing platform, announced the opening of Rheonix Laboratories LLC, a CLIA-certified clinical laboratory located in Ithaca, New York. Rheonix Laboratories is permitted by New York State to provide COVID PCR testing and results, and will be partnering with organizations, including pharmacies, schools, long-term care facilities and county and municipal health departments, to provide low-cost testing to their populations.

The laboratory’s COVID PCR testing program enables seamless registration, sample collection, and testing for individuals and organizations, the company says.

Rheonix Laboratories says it provides reliable, rapid turnaround COVID PCR testing utilizing the Rheonix COVID-19 MDx Assay, which was first granted emergency use authorization (EUA) by the U.S. Food and Drug Administration in April 2020. The assay is highly sensitive and detects all COVID-19 variants of concern, including the Omicron subvariants. Individuals can register online for a test using the Rheonix Laboratories Patient Portal. Sample types include saliva and nasal swabs. Results are expected within 24 hours after receipt of sample and can be viewed conveniently and securely through the portal.

“Offering testing through an affiliated laboratory is an important extension of Rheonix’s core mission: to offer molecular diagnostics to more people, in more places, more often,” says Greg Galvin, president, CEO and Chairman of the Board of Directors of Rheonix. “The initial focus of Rheonix Laboratories is to provide a convenient and economical COVID-19 PCR testing option for organizations and community members. In the future, we plan to offer additional assays at the laboratory, including syndromic panels for respiratory, gastrointestinal and sexually transmitted infections.”

Since early in the pandemic, Rheonix has been a leading provider of COVID testing capacity in the mid-Atlantic and Northeastern United States. The company has been instrumental in providing easily scalable COVID-19 PCR testing capacity to community hospitals and local clinical laboratories, reducing turnaround time from two weeks to same day. Since April 2020, U.S. laboratories have processed more than 1 million samples using Rheonix’s COVID-19 testing system.